Investigational Agent AG-013736 In Combinations With Standard Of Care Treatments For Patient's With Advanced Solid Tumor

Completed · Phase 1

Conditions studied: Neoplasms

In brief

To determine the best dose of this investigational agent AG-013736 in combination with various standard of care treatments for advanced solid tumors.

Key facts

Study ID

NCT00454649

Run by

Pfizer

People needed

102

Starts

2005-12-01

Expected to finish

2011-04-01

Last updated by the study team

2012-04-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Advanced solid tumors suitable for treatment with Taxanes, with or without carboplatin, or treatment with Capecitabine, Gemcitabine/Cisplatin. or Pemetrexed/Cisplatin

You may not qualify if…

• Tumors abutting or providing support for blood vessels
• Any significant gastrointestinal abnormalities or active bleeding.

Where it is running

• Pfizer Investigational Site — Augusta, Georgia, United States
• Pfizer Investigational Site — Augusta, Georgia, United States
• Pfizer Investigational Site — Harvey, Illinois, United States
• Pfizer Investigational Site — Harvey, Illinois, United States
• Pfizer Investigational Site — Tinley Park, Illinois, United States
• Pfizer Investigational Site — Hobart, Indiana, United States
• Pfizer Investigational Site — Munster, Indiana, United States
• Pfizer Investigational Site — Philadelphia, Pennsylvania, United States
• Pfizer Investigational Site — Houston, Texas, United States
• Pfizer Investigational Site — Kennewick, Washington, United States
• Pfizer Investigational Site — Warsaw, Poland
• Pfizer Investigational Site — Barcelona, Barcelona, Spain
• Pfizer Investigational Site — Madrid, Madrid, Spain

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.